Categories Earnings, Health Care

Amarin Corporation (AMRN): Q4 2019 Earnings Snapshot

Amarin Q4 earnings

— Amarin Corporation plc (NASDAQ: AMRN) reported earnings of $0.04 per share in the fourth-quarter 2019 vs. $0.02 per share loss expected.  

— Revenue grew 85% to $143.3 million, versus $136.01 million expected. Net product revenue increased 84% year-over-year to $142 million, driven mainly by an increase in total Vascepa prescriptions in the US. 

— For full-year 2020, Amarin expects revenues to be $650 million to $700 million.

— AMRN shares gained 2% during the aftermarket hours. 

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Key takeaways from JM Smucker’s (SJM) Q4 2025 earnings report

Shares of The J.M. Smucker Co. (NYSE: SJM) plunged 15% on Tuesday after the company delivered mixed results for the fourth quarter of 2025. While earnings came ahead of expectations,

J.M. Smucker (SJM) Q4 2025 Earnings: Key financials and quarterly highlights

The J.M. Smucker Co. (NYSE: SJM) reported its fourth quarter 2025 earnings results today. Net sales was $2.1 billion, down 3% year-over-year. Comparable net sales decreased 1%. Net loss was

Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials

Plus Therapeutics (NASDAQ: PSTV) is a pharmaceutical company engaged in the development of targeted radiotherapeutics for difficult-to-treat cancers. Currently, it is advancing a pipeline of product candidates with lead programs

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top